ReviewBehavioural brain research2015
Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.
Review in Behavioural brain research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 142 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
142 citing papers in PubMed, 3 syntheses or guidelines pooled it, 300 citations in OpenAlex.
- A systematic review of the pharmacokinetics of classical serotonergic psychedelic compounds in healthy adult subjects.Journal of psychopharmacology (Oxford, England) · 2026Pooled it
- The Role of the Serotonergic System in Time Perception: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies.Addiction biology · 2022Pooled it
- Trial
- The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial.Psychopharmacology · 2019Trial
- Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting.Psychopharmacology · 2018Trial
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.Journal of psychopharmacology (Oxford, England) · 2016Trial
- LSD alters eyes-closed functional connectivity within the early visual cortex in a retinotopic fashion.Human brain mapping · 2016Trial
- Investigation of the pharmacological and circuit basis for psychedelic drug effects on interval timing in mice.Psychopharmacology · 2026Article
- A circuit dissection of perception-action decoupling in S-ketamine-induced hallucination-like states.Molecular psychiatry · 2026Article
- In-silico toxicity study of tryptamine, psilocin, psilocybin, N,N-dimethyltryptamine, 5'-methoxy-N,N-dimethyltryptamine and O-acetylpsilocin.Archives of toxicology · 2026Article
- Convergent neuroimmune signaling underlying rapid antidepressant response to ketamine and psychedelics.Molecular psychiatry · 2026Article
- Classic Psychedelics for Treating Chronic Pain: Mechanism and Clinical Translation.Molecules (Basel, Switzerland) · 2026Review
- Facing trauma under the influence of psychedelics: A phenomenological study with Nova rave survivors.Journal of psychopharmacology (Oxford, England) · 2026Article
- Role of neural oscillations in depression: highlights on gamma oscillations.Translational psychiatry · 2026Review
- Pharmacodynamic effects and plasma pharmacokinetics of N, N-dimethyltryptamine after intranasal versus subcutaneous administration in male rats.Psychopharmacology · 2026Article
- The synaptic triad in depression: how stress-related pathways converge on BDNF, NMDA receptor, and MMP-9.Pharmacological reports : PR · 2026Review
- Integrated Computer-Aided Drug Design: Advances in GPCR Natural Ligand Discovery.Cell biochemistry and biophysics · 2026Review
- DMT-Induced Shifts in Criticality Correlate with Self-Dissolution.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2026Article
- Restoring oscillatory dynamics in Alzheimer's disease: A laminar whole-brain model of serotonergic psychedelic effects.Network neuroscience (Cambridge, Mass.) · 2026Article
82 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Serotonergic hallucinogens, such as (+)-lysergic acid diethylamide, psilocybin, and mescaline, are somewhat enigmatic substances. Although these drugs are derived from multiple chemical families, they all produce remarkably similar effects in animals and humans, and they show cross-tolerance. This article reviews the evidence demonstrating the serotonin 5-HT2A receptor is the primary site of hallucinogen action. The 5-HT2A receptor is responsible for mediating the effects of hallucinogens in human subjects, as well as in animal behavioral paradigms such as drug discrimination, head twitch response, prepulse inhibition of startle, exploratory behavior, and interval timing. Many recent clinical trials have yielded important new findings regarding the psychopharmacology of these substances. Furthermore, the use of modern imaging and electrophysiological techniques is beginning to help unravel how hallucinogens work in the brain. Evidence is also emerging that hallucinogens may possess therapeutic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.